Javascript must be enabled to continue!
Dendrimers: Advancing Therapeutic Strategies for Dementia
View through CrossRef
Abstract:
Dementia, characterized by a progressive decline in cognitive function, poses a significant
challenge to global healthcare systems, with current therapeutic approaches offering limited
efficacy. The development of nanotechnology-based drug delivery systems has introduced promising
avenues for enhancing the treatment of neurodegenerative disorders such as Alzheimer’s disease.
Dendrimers, with their highly branched, nanoscale structure, provide an innovative platform
for targeted drug delivery to the brain. Dendrimers serve as nanoscale drug carriers that facilitate
controlled drug release, enhance bioavailability, and improve penetration across the blood-brain
barrier (BBB), leading to superior therapeutic efficacy in neurodegenerative disorders. In particular,
dendrimers can encapsulate both hydrophilic and hydrophobic drugs, increasing their stability
and minimizing systemic side effects. This review explores the unique properties of dendrimers,
focusing on their potential as drug delivery vehicles in dementia treatment. We also highlight advancements
in the design and application of dendrimer-based therapeutics, emphasizing their role
in targeting key pathological mechanisms underlying dementia. Through these approaches, dendrimers
represent a promising strategy for developing more effective and personalized treatment
modalities for patients suffering from cognitive impairment and dementia.
Title: Dendrimers: Advancing Therapeutic Strategies for Dementia
Description:
Abstract:
Dementia, characterized by a progressive decline in cognitive function, poses a significant
challenge to global healthcare systems, with current therapeutic approaches offering limited
efficacy.
The development of nanotechnology-based drug delivery systems has introduced promising
avenues for enhancing the treatment of neurodegenerative disorders such as Alzheimer’s disease.
Dendrimers, with their highly branched, nanoscale structure, provide an innovative platform
for targeted drug delivery to the brain.
Dendrimers serve as nanoscale drug carriers that facilitate
controlled drug release, enhance bioavailability, and improve penetration across the blood-brain
barrier (BBB), leading to superior therapeutic efficacy in neurodegenerative disorders.
In particular,
dendrimers can encapsulate both hydrophilic and hydrophobic drugs, increasing their stability
and minimizing systemic side effects.
This review explores the unique properties of dendrimers,
focusing on their potential as drug delivery vehicles in dementia treatment.
We also highlight advancements
in the design and application of dendrimer-based therapeutics, emphasizing their role
in targeting key pathological mechanisms underlying dementia.
Through these approaches, dendrimers
represent a promising strategy for developing more effective and personalized treatment
modalities for patients suffering from cognitive impairment and dementia.
Related Results
Dendrimers
Dendrimers
Abstract
Dendrimers have globular and well‐controlled structures, and they are produced by organic synthesis. There are two types of synthetic pathway: divergent methods ...
Prescription Patterns of Anti-dementia and Psychotropic Drugs in People Living With Dementia in China
Prescription Patterns of Anti-dementia and Psychotropic Drugs in People Living With Dementia in China
Abstract
Pharmacotherapy of dementia is a critical intervention for managing symptoms of and slowing progression of dementia. However, evidence on prescribing patter...
Lipophilic PAMAM Dendrimer: Conceptualization of Targeted Cosmetics
and Drug Delivery
Lipophilic PAMAM Dendrimer: Conceptualization of Targeted Cosmetics
and Drug Delivery
Abstract:
The structure, properties, synthesis, negligible toxicity, and surface modification of PAMAM (polyamidoamine dendrimers) are all discussed in this review. The properties ...
MBI‐apathy, ApoEɛ2, and risk for Alzheimer disease dementia
MBI‐apathy, ApoEɛ2, and risk for Alzheimer disease dementia
AbstractBackgroundApathy, characterized by decreased interest, initiative, and emotional reactivity, is amongst the most common neuropsychiatric symptoms in dementia. However, apat...
Walking pace, handgrip strength, age, APOE genotypes, and new-onset dementia: the UK Biobank prospective cohort study
Walking pace, handgrip strength, age, APOE genotypes, and new-onset dementia: the UK Biobank prospective cohort study
Abstract
Background
The independent and additive associations of walking pace and grip strength on dementia risk and the potential modifying effects...
Prevalence, Factors Associated and Knowledge of Dementia in a Sample of Older Ugandans
Prevalence, Factors Associated and Knowledge of Dementia in a Sample of Older Ugandans
Abstract
Introduction:Dementia is on the rise due to increasing proportion of old people in Sub-Saharan Africa (SSA). Although dementia is misattributed to normal ageing or...
Rural general practitioner confidence in diagnosing and managing dementia: A two‐stage, mixed methods study of dementia‐specific training
Rural general practitioner confidence in diagnosing and managing dementia: A two‐stage, mixed methods study of dementia‐specific training
AbstractIntroductionDementias a prevalent chronic healthcare condition affecting 46 million people worldwide and projected to grow in the coming years. Australians living in rural ...
Dendrimers Chemistry and Applications: A Short Review
Dendrimers Chemistry and Applications: A Short Review
Dendrimers, also known as cascade molecules, arborols, cauliflower or starburst polymers. They are monodisperse, symmetrical, macromolecules with tree like 3D-architecture consists...

